Head & Neck Cancer Drugs Market Overview:
The global head & neck cancer drugs market was valued at $1,295 million in 2017, and is projected to reach $2,281 million by 2025, registering a CAGR of 7.3% from 2018 to 2025.
Head & neck cancers include a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. There are different types of drugs used alone or in combination for treatment of head & neck cancer. Although traditional chemotherapeutic drugs preferably used in combination of radiation therapy, targeted immune therapies are emerging as a standard treatment option for advanced-stage head & neck cancers.
Increase in prevalence of head & neck cancer across geographies, rise in demand for combination therapy for management of head & neck cancer, and growth in number of R&D activities to develop ideal therapeutic drive the growth of the global head & neck cancer drugs market. Furthermore, technological advancements in screening procedure for cancer and strong presence of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, Durvalumab, Erlotinib, Afatinib, Bevacizumab, and others are expected to drive the market growth. In addition, rise in number of risk factors such as growth in number of cigarette smoking, alcohol & tobacco consumption is further anticipated to fuel the growth of the global head & neck cancer drugs market.
Head & Neck Cancer Drugs Market Segmentation
The global head & neck cancer drugs market is segmented based on drug class, sales channel, and region. Based on drug class, the market is classified into chemotherapy, immunotherapy, and targeted therapy. According to the sales channel, it is categorized into hospital pharmacies, drug stores & retail pharmacies, and online stores. Based on region, the head and neck cancer drugs market size is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).
Segment review
Based on drug class, the head & neck cancer drugs market is classified into chemotherapy, immunotherapy, and targeted therapy. The chemotherapy segment occupied the largest head & neck cancer drugs market share, this is attributed to increase in usage of chemotherapeutic drugs during radiation therapy and rise in benefits of combination therapy. Currently, drugs such as bleomycin, cetuximab, docetaxel, paclitaxel, capecitabine, hydroxyurea, methotrexate, docetaxel, 5-fluorouracil, and methotrexate are approved for treatment of head & neck cancer. Therefore, surge in prevalence of head & neck cancer and rise in adoption of chemotherapeutics for treatment of head & neck cancer along with other therapeutics drive the market growth of this segment. However, chemotherapeutic agents are cytotoxic that harm malignant as well as healthy cells in cancer patients, which is a major factor that restrains the growth of the market. Moreover, the demand for immunotherapy is expected to increase during the forecast period due to rise in adoption of targeted immune therapeutics drugs and strong presence of pipeline drugs. Drugs such as Pembrolizumab (Keytruda) by Merck & Company and Nivolumab (Opdivo), developed by Bristol-Myers Squibb are approved by the U.S. food and drug administration (FDA) for the treatment of recurrent or metastatic head & neck squamous cell carcinoma (HNSCC), which has not been stopped by platinum-based chemotherapy. Expected launch of pipeline drugs such as Ipilimumab, Atezolizumab, Avelumab, and Durvalumab is expected to further drive the market growth.
Based on sales channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. The online providers segment is expected to experience fastest growth over the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in number of internet users, and growth in awareness about online pharmacy. However, drug stores & retail pharmacies segment dominated the market in 2017 due to its higher presence.
Snapshot of Asia-Pacific head & neck cancer drugs market
Asia-Pacific presents lucrative growth opportunities for the key players operating in the head & neck cancer drugs market owing to large population base, surge in incidence of head & neck cancer, and increase in demand for head & neck cancer combination therapeutics. Risk factors such as growth in alcohol consumption, increase in cigarette smoking, and higher usage of tobacco are further expected to fuel the market growth. Betel quid chewing is the most common form of tobacco chewing in the Asia-Pacific region. Furthermore, increase in awareness toward treatment & early screening of the disease and rise in healthcare expenditure fuel the growth of the market in this region.
The key players profiled in this report include AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company (ARMO Biosciences), Fortress Biotech, Inc. (Checkpoint Therapeutics, Inc.), F. Hoffmann-La Roche Ltd. (Genentech, Inc.), Immutep Limited, Merck & Co., Inc., Merck KGaA (EMD Serono, Inc.), Novartis AG, and Pfizer Inc.
Key Benefits for Head & Neck Cancer Drugs Market:
- The study provides an in-depth analysis of the market along with the current head & neck cancer drugs market trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2017 to 2025, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
- Head & neck cancer drugs market forecast is studied from 2018 to 2025.
- A comprehensive analysis of all the geographical regions is provided to determine the prevailing opportunities.
- Head & neck cancer drugs market size and estimations are based on a comprehensive analysis of key developments in the head and neck cancer drugs industry.
- The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Head & Neck Cancer Drugs Market Report Highlights
| Aspects | Details |
 By Drug Class |
|
 By Sales Channel |
|
 By Region |
|
 Key Market Players | Eli Lilly and Company, F. Hoffmann-La Roche Ltd. (Genentech, Inc.,), Teva Pharmaceutical Industries Limited, Sanofi, Bristol-Myers Squibb Company, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Merck & Co., Inc., Fresenius Medical Care AG & Co. KGaA, AstraZeneca Plc. |
Analyst Review
Head & neck cancer includes the cancers of mouth, nose, throat, larynx, sinuses, or salivary glands. Drugs such as chemotherapy, immune therapy, and targeted therapy are used for treatment of head & neck cancers. The adoption of head & neck cancer drugs is expected to increase due to rise in the prevalence of head & neck cancer across the world and increase in adoption of combination therapy along with radiation therapy and surgical procedures.
Rise in R&D studies for the development of ideal therapeutics, strong presence of pipeline drugs, and growth in adoption of head & neck cancer drugs are projected to supplement the market growth during the forecast period. Moreover, rise in number of risk factors such as growing cigarette smoking, alcohol & tobacco consumption is further expected to fuel the market growth. However, complications associated with the use of head & neck cancer drugs can hinder the market growth.
North America is expected to remain dominant during the forecast period due to surge in use of head & neck cancer drugs owing to wide presence of advanced therapeutics, higher number of target population. In addition, Asia-Pacific and LAMEA are expected to offer lucrative growth opportunities to the key players during the forecast period due to increase in incidence of head & neck cancer, improvement in healthcare infrastructure with developing economies, and growth in the need for combination therapy.
Loading Table Of Content...
